Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
Reza Shojaei, Executive Leader, Strategic Growth Advisor in Health and Biopharma, shared on LinkedIn:
”Are Hemoglobin Oxygen Carriers (HBOCs) a breakthrough waiting to happen, or just hype?
What if we could deliver oxygen without relying on blood donors, refrigeration, or blood typing?
That’s the bold promise of Hemoglobin Oxygen Carriers (HBOCs), sometimes called “artificial blood.”
Approved in South Africa, tested in Japan, funded by the U.S. military, and eyed for organ preservation in Europe… yet still viewed with caution by regulators.
So, are HBOCs a breakthrough waiting to happen, or just hype?’
In this newsletter edition, we explore:
- Where HBOCs stand today
- Their advantages and safety challenges
- Whether they can truly replace blood donation
- What the global market looks like in 2025
- If they’re viable for low- and middle-income countries”
Read the full Blood and Plasma Pulse newsletter edition here.
Stay updated on the emerging in the field of hematology with Hemostasis Today.
-
Mar 17, 2026, 15:55Mostafa Faisal Mohammed Saleh: Evidence-Based Recommendations for Hodgkin Lymphoma Management in LMICs
-
Mar 17, 2026, 15:50Yogesh Kalkonde: Advancing Sickle Cell Care Through Primary Health Training
-
Mar 17, 2026, 15:49Melissa Hollo: Closing the Gap in Maternal Anemia Care Through HerCare
-
Mar 17, 2026, 15:46Simon Senanu: Rouleaux Formation – When Red Cells Stack Like Coins
-
Mar 17, 2026, 15:45Heghine Khachatryan: Hidden Hematologic Causes of Cryptogenic Stroke
-
Mar 17, 2026, 15:45Wolfgang Miesbach: Six Years of Normal Factor VIII After a Single Gene Therapy in Hemophilia A
-
Mar 17, 2026, 15:44Jan Sloves: Venous Phasicity and the Role of IVC Mechanics
-
Mar 17, 2026, 15:43How Clinicians Navigate the Challenge of Balancing Clotting and Bleeding in CAD – Vasculearn Network
-
Mar 17, 2026, 15:41Beverly G. Tchang: Lipid-Lowering Therapy in Women During Pregnancy and Lactation